A PHASE II STUDY OF CHOP MAS RITUXIMAB WITH INTRATECAL METOTREXATE FOLLOWED BY RADIOTHERAPY IN PATIENTS WITH NON-HODGKIN PRIMARY LYMPHOMA TESTICULAR

Phase 1

• Conditions: -C829 Follicular lymphoma, unspecified; Follicular lymphoma, unspecified; C829

• Registration Number: PER-081-03
• Lead Sponsor: INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-01-22
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

NLC Testicular Primary
Stage 1 to II Ann Arbor
Untreated disease
Evaluable, measurable two-dimensionally or without evidence of diseases
Age = 18 years
ECOG performance status 0-2.

Exclusion Criteria

- Impaired renal function (creatinine> 2 mg / day) or liver function
(bilimibin> 2mg / di) except due to lymphoma.
- Patients with HIV positive
- Evolutionary malignancy within 5 years with the exception of cancer
Localized skin does not melamomic.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br>Outcome name:Adverse Events Serious.<br>Unacceptable toxicity, defined as unpredictable, irreversible or grade 4.<br>The refusal of the patient to continue therapy.<br>Measure:Therapeutic activity of systematic chemotherapy combined with the addition of Rituximab + Qt. intrathecal + loco-regional radiotherapy in primary testicular DLCL.<br>Timepoints:at month<br>

Secondary Outcome Measures

Name	Time	Method
<br>Outcome name:not contemplated<br>Measure:not contemplated<br>Timepoints:not contemplated<br>